Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors

Summary

CVM-1118 (TRX-818) is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human is evaluated from the phase 1 study. The objectives of the phase 2 study is to further investigate the efficacy of CVM-1118 for patients with advanced neuroendocrine tumors.

Timeline

Start

2018-12-15

Primary completion

2024-09-30

Completion

2026-03-31

Publications

• Yen CJ, Chen MH, Chen YY, Bai LY, Chen JS, Hsieh JC, Shih YH, Wu IC, Chen YL, Chen CM, Chao TY, Chu YW, Chien DS. Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial. Br J Cancer. 2026 Jul 2. doi: 10.1038/s41416-026-03515-w. Online ahead of print.

Drugs

Indications